Anagrelide controlled release - Galena Biopharma

Drug Profile

Anagrelide controlled release - Galena Biopharma

Alternative Names: Anagrelide CR - Galena Biopharma; CR anagrelide - Galena Biopharma; GALE-401

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Mills Pharmaceuticals
  • Developer Galena Biopharma
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic myeloid leukaemia; Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera

Most Recent Events

  • 12 Sep 2016 Galena Biopharma has patent protection for GALE 401 in Japan
  • 09 Aug 2016 Galena Biopharma plans a phase III trial for Essential thrombocythemia ,
  • 13 Jun 2016 Adverse events data from a pooled analysis presented at the 21st Congress of the European Haematology Association (EHA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top